CemiplimAb-rwlc Survivorship and Epidemiology (CASE): A prospective study of the safety and efficacy of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC) in a real-world setting

Main Article Content

Guilherme Rabinowits
Jade Homsi
Soo Park
Nikhil Khushalani
Timothy Panella
David Ellison
Rhonda Gentry
Suraj Venna
John Strasswimmer
Richard Zuniga
Sunandana Chandra
Emily Ruiz
Michael Migden
Sherrif Ibrahim
Nikita Mehta
Timothy Inocencio
Xuanyao He
Haixin Zhang
Kathryn Gillis
Jean-Francois Pouliot

Keywords

cemiplimab

References

1. de Jong E et al. J Eur Acad Derm Venereol. 2021;36(Suppl. 1):6–10.

2. Burova E et al. Mol Cancer Ther. 2017;16:861–870.

3. Regeneron Pharmaceuticals, Inc. LIBTAYO® [cemiplimab-rwlc] injection full US prescribing information. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761097s007lbl.pdf [Accessed Jul 9, 2022].

4. European Medicines Agency. LIBTAYO® EPAR. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/libtayo [Accessed Jul 25, 2022].

Most read articles by the same author(s)

<< < 1 2 3 > >>